NASDAQ:ZURA Zura Bio Q2 2026 Earnings Results & Report $4.00 -0.13 (-3.15%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.11 +0.11 (+2.85%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zura Bio missed analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.21 versus the -$0.1913 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeBefore Market OpensConference Call7:00 AM ET Zura Bio EPS ResultsActual EPS-$0.21Consensus EPS -$0.1913Beat/MissMissed by -$0.0187One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersZura Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsZura Bio's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zura Bio Q2 2026 Earnings FAQ Did Zura Bio beat earnings estimates for Q2 2026? Zura Bio (NASDAQ:ZURA) reported earnings of -$0.21 per share for Q2 2026, missing the consensus estimate of -$0.1913. The report was announced on Tuesday, August 11, 2026. When is Zura Bio's next earnings date? Zura Bio's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zura Bio on the company's earnings history page. Zura Bio Earnings HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)October 9 at 11:00 PM | theglobeandmail.comThis biotech stock is a top pick at GuggenheimOctober 7 at 8:45 AM | finance.yahoo.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 10 at 1:00 AM | Weiss Ratings (Ad)Zura Bio (NASDAQ:ZURA) Shares Down 0.7% - Here's What HappenedOctober 3, 2026 | americanbankingnews.comZura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo FinanceSeptember 17, 2026 | finance.yahoo.comZura Bio (ZURA) Hits Enrollment Milestones As Losses Widen SharplySeptember 11, 2026 | finance.yahoo.comSee More Zura Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email. Email Address About Zura BioZura Bio (NASDAQ:ZURA), Inc. is a clinical-stage biotechnology company focused on developing medicines for chronic immune-mediated diseases. The company’s research programs are designed to address conditions in which abnormal immune responses contribute to inflammation and tissue damage. Zura Bio is advancing a pipeline of investigational antibody-based therapies for diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and systemic sclerosis. Its programs target biological pathways involved in inflammation, with the goal of developing treatments for patients who may not respond adequately to existing therapies. The company’s candidates remain under clinical evaluation and have not been approved for commercial use. Based in the United States, Zura Bio conducts development activities and clinical studies through a global network of research sites and medical institutions. The company became a publicly traded business through a business combination with JATT Acquisition Corp. and began trading on the Nasdaq under the symbol ZURA in 2023.View Zura Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
